The oncolytic adenovirus VCN01 promotes anti tumor effect in primitive neuroectodermal tumor models
Keywords: 
Materias Investigacion::Ciencias de la Salud::Oncología
Issue Date: 
2019
Publisher: 
Springer Science and Business Media LLC
ISSN: 
2045-2322
Note: 
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Citation: 
Garcia-Moure, M. (Marc); Martinez-Velez, N. (Naiara); Gonzalez-Huarriz, M. (Marisol); et al. "The oncolytic adenovirus VCN01 promotes anti tumor effect in primitive neuroectodermal tumor models". Scientific Reports. 9 (14368), 2019, 1 - 10
Abstract
Last advances in the treatment of pediatric tumors has led to an increase of survival rates of children affected by primitive neuroectodermal tumors, however, still a significant amount of the patients do not overcome the disease. In addition, the survivors might suffer from severe side effects caused by the current standard treatments. Oncolytic virotherapy has emerged in the last years as a promising alternative for the treatment of solid tumors. In this work, we study the anti-tumor effect mediated by the oncolytic adenovirus VCN-01 in CNS-PNET models. VCN-01 is able to infect and replicate in PNET cell cultures, leading to a cytotoxicity and immunogenic cell death. In vivo, VCN-01 increased significantly the median survival of mice and led to long-term survivors in two orthotopic models of PNETs. In summary, these results underscore the therapeutic effect of VCN-01 for rare pediatric cancers such as PNETs, and warrants further exploration on the use of this virus to treat them.

Files in This Item:
Thumbnail
File
s41598-019-51014-1.pdf
Description
Size
1.67 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.